Novo Nordisk CEO sees 'long runway' for weight-loss drugs as obesity grips America
The boom in weight-loss drugs may have transformed the obesity market, but Novo Nordisk's CEO says the industry is still only scratching the surface with tens of millions of Americans potentially eligible for treatment.Novo Nordisk President and CEO Mike Doustdar joined FOX Business' Cheryl Casone...
FOXBusiness.com - Business/Financial